ASCO GI: mTOR Inhibitor Slows Advanced pNET (CME/CE)
SAN FRANCISCO (MedPage Today) — Patients with advanced pancreatic neuroendocrine tumors (pNET) had more than a twofold increase in progression-free survival when treated with a mammalian target of rapamycin (mTOR) inhibitor, investigators reported.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com